Recent news on Trastuzumab

ImmunoGen, Inc. Announces Clinical Findings for Three TAP ...  -  25 May 2007
PharmaLive.com (press release),Four TAP compounds are already in clinical testing - huN901-DM1 and huC242-DM4, in development by ImmunoGen, trastuzumab-DM1, in development by Genentech,

GlaxoSmithKline Reports Further Progress of Oncology Portfolio  -  25 May 2007
PR Newswire (press release),HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab, and which was approved this week in Switzerland.

Approvals: Herceptin, Reyataz, and Peg-Intron  -  May 21, 2007
Medscape (subscription)May 21, 2007 — The European Commission has approved a new indication for trastuzumab infusion, allowing its use with hormonal therapy in the treatment of

Gene Patenting -- Steep Cost For Health Care And Patients  -  May 10, 2007
Medical News Today (press release),The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for

GlaxoSmithKline Reveals Further Progress Of Oncology Portfolio ...  -  May 24, 2007
Trading Markets,...or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

First green light for Tyverb in Europe  -  May 24, 2007
Pharma Times (subscription),...with advanced breast cancer, and in women with HER-2 positive breast cancer who are unresponsive to therapy with Roche's Herceptin (trastuzumab).

NICE chairman rejects "industry influence" claims  -  May 24, 2007
Pharma Times (subscription),He also robustly dismissed Labour MP Dr Howard Stoate's view that NICE's decision to recommend Roche's breast cancer treatment Herceptin (trastuzumab) was

COMUNICADO: Se aprueba la utilización de Herceptin(R) en Europa en ...  -  May 3, 2007
Terra España,...(i) Kaufman, B. Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormone-dependent metastatic

Kosan Announces May 9, 2007 Conference Call and Webcast of First ...  -  Apr 30, 2007
PR Newswire (press release),NOTE: Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc. Herceptin(R) (trastuzumab) is a registered trademark of

Is Immunogen Helping to Build a 'Supercharged' Herceptin?  -  May 16, 2007
Seeking Alpha,Again, a nice lineup of both clinical and preclinical opportunities, headlined, at least for me, by what’s innocuously labeled “Trastuzumab-DM1� (this does

Kosan Announces First Quarter 2007 Financial Results; Plans to ...  -  May 9, 2007
PR Newswire (press release),Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc. Selected Financial Information Condensed Statements of Operations (in thousands,

ImmunoGen, Inc. Announces Resignation of Howard Pien from its ...  -  May 17, 2007
Genetic Engineering News (press release),...in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Multiple compounds are in research/preclinical development.

Roche opens biotech production facility in Basel  -  May 14, 2007
OutSourcing-Pharma.com,...at Roche's Penzberg site in Germany, will initially produce the active ingredient for another key oncology product, Herceptin (trastuzumab), in Europe.

Combination treatment stymies breast cancer growth  -  May 14, 2007
SpiritIndia,..."These tumors are initially highly sensitive to a drug known as trastuzumab or Herceptin, one of the drugs used in combination in the mouse study and which

UK 'worst on cancer drug access'  -  May 9, 2007
BBC News,In the UK, the first sale of breast cancer drug trastuzumab was in autumn 2000, nearly two years after it hit the market in the US and a full 12 months

SAFC adds to biologics portfolio  -  May 10, 2007
BiopharmaReporter.com,Already, 14 biologic drugs have been approved in the US and in other countries, notably Roche/Genentech's Herceptin (trastuzumab) for breast cancer,

UK 'worst on cancer drug access'  -  May 9, 2007
BBC News,In the UK, the first sale of ... trastuzumab was in autumn 2000, nearly two years after it hit the market in the US and a full 12 months after it was given

Lonza plans to commercially produce emerging class of drugs  -  May 10, 2007
DrugResearcher.com,...notably Roche/Genentech's Herceptin (trastuzumab) for breast cancer, Genentech/Biogen Idec's lymphoma treatment Rituxan (infliximab) and colorectal

Avastin Launched In Europe For Metastatic Breast Cancer  -  May 8, 2007
Medical News Today,AVEREL will combine Avastin with Herceptin (trastuzumab) plus chemotherapy. In early breast cancer, E5103 is investigating adding Avastin to standard

BIO 2007: Return To Boston Underscores Industry's Growth  -  May 6, 2007
BioWorld Online,And in 2000, only one targeted cancer therapy had gained the FDA's blessing, South San Francisco-based Genentech Inc.'s Herceptin (trastuzumab),

Herceptin® Approved Combined With Aromatase Inhibitor For HER2 ...  -  May 5, 2007
Medical News Today (press release),Roche announced today that the European Commission has approved the use of Herceptin® (trastuzumab) in combination with an aromatase inhibitor for the

Herceptin gets European okay in combination with Arimidex  -  May 4, 2007
Pharma Times (subscription),The European Commission has given the go-ahead for the use of Herceptin (trastuzumab) in combination with an aromatase inhibitor for the treatment of

Don’t be misled by PHARMAC bearing gifts!  -  May 3, 2007
Scoop.co.nz,...its messages to cells to grow aggressively. It also stimulates the body’s natural immune system to fight back. The other name for Herceptin is Trastuzumab.

Tamoxifen Protects Certain Women at High Risk for Breast Cancer  -  May 2, 2007
Forbes,The team added two cancer drugs, gefitinib and pertuzumab, to Herceptin (trastuzumab) to help slow the growth of tumors with higher levels of a protein

Herceptin(R) Approved in Europe for use in Combination With an ...  -  May 2, 2007
PR Newswire UK (press release),Roche announced today that the European Commission has approved the use of Herceptin(R) (trastuzumab) in combination with an aromatase inhibitor for the

Herceptin(R) Approved in Europe for use in Combination With an ...  -  May 2, 2007
Earthtimes.orgRoche announced today that the European Commission has approved the useof Herceptin(R) (trastuzumab) in combination with an aromatase inhibitor forthe

Drug combination helps certain breast cancer cases  -  May 1, 2007
Scientific AmericanSchiff and colleagues tested an experimental drug called pertuzumab and trastuzumab, sold under the brand name Herceptin. Both are made by Genentech,

Drug combination helps certain breast cancer cases  -  May 1, 2007
ReutersSchiff and colleagues tested an experimental drug called pertuzumab and trastuzumab, sold under the brand name Herceptin. Both are made by Genentech (DNA.

Drug Combination Halts Tumor Growth Better Than Single Agent  -  May 2, 2007
Medical News Today (press release),Some mice received one of three HER inhibitors - pertuzumab, trastuzumab, or gefitinib - or a combination of two or three of the drugs.

ImmunoGen, Inc. Announces Conference Call to Discuss its Third ...  -  26 Apr 2007
PharmaLive.com (press release),...collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-MCC-DM1, in development by Genentech.

Shortened HER2 Gene Responds To Lapatinib, Not Trastuzumab  -  Apr 22, 2007
Medical News Today (press release),Breast cancer cells expressing a shortened form of the HER2 gene can be treated with lapatinib, but they are resistant to another drug known as trastuzumab.

Identifying Who Responds to Herceptin  -  Apr 24, 2007
Cancerpage.com,..."The detection of p95HER2 in biopsies of HER2-positive breast cancer patients may predict a poor response to trastuzumab, an anti-HER2 antibody commonly

Clinical Trials Update: Adjuvant Trastuzumab, Adjuvant Endocrine ...  -  Apr 18, 2007
DG NewsThe use of trastuzumab, a monoclonal antibody, has also been explored in the adjuvant setting through several large trials, such as the National Surgical

How does trastuzumab work?  -  Apr 1, 2007
The Mercury (subscription),Trastuzumab (Herceptin) specifically targets and binds to the HER2 (cancer) receptors on the tumour cell surface. It may decrease the number of messages

The High Cost of New Cancer Therapies Has Made Them Targets for ...  -  Apr 20, 2007
PharmaLive.com (press release),...or metastatic breast cancer in combination with Xeloda (capecitabine) in women who have received prior therapy, including Herceptin (trastuzumab).

GSK gets FDA nod for cancer drug  -  Apr 4, 2007
Express Pharma,...or metastatic breast cancer whose tumours over express HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

Marker Associated with Response to Herceptin® in Breast Cancer  -  Apr 25, 2007
Cancer Consultants (press release),HER2-overexpressing cancer cells, those whose cells express a receptor called p95HER2 have poor anticancer response rates to Herceptin® (trastuzumab).

Research shows Herceptin helps  -  Apr 1, 2007
The Mercury (subscription),A trial including 469 women has shown that the combination of trastuzumab (Herceptin) with chemotherapy yielded a 45% overall response rate, compared to a

GSK seeks approval for lapatinib for breast cancer patients in Japan  -  Apr 2, 2007
SpiritIndia,...with advanced or metastatic HER2 positive breast cancer in women who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

Major Clinical Breast Cancer Study Begins  -  Apr 4, 2007
Post Chronicle...look at the safety and benefit of adding lapatinib (Tykerb) to trastuzumab (Herceptin) for the treatment of early stage HER2-positive breast cancer.

Kosan Presents Preclinical Data on Nuclear Export Inhibitors ...  -  Apr 18, 2007
PharmaLive.com (press release),NOTE: Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc. Herceptin(R) (trastuzumab) is a registered trademark of

VioQuest Pharmaceuticals Announces Data Presentation for Its Akt ...  -  Apr 19, 2007
PR Newswire (press release),VQD-002 has also shown compelling preclinical activity in combination with other targeted therapies such as Herceptin (trastuzumab), and other tyrosine

Human Tissue Transgenic Cancer Model may Offer Significant Advance ...  -  Apr 19, 2007
ADMET.net (press release),..."We have been very encouraged by the similarity to human patients in both histological appearance and response to agents like Herceptin® (trastuzumab),�

Kosan Presents Preclinical Data on Nuclear Export Inhibitors ...  -  Apr 18, 2007
PR Newswire (press release),...multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab).

Novel Human Tissue Transgenic Cancer Model May Offer Significant ...  -  Apr 18, 2007
PharmaLive.com (press release),We have been very encouraged by the similarity to human patients in both histological appearance and response to agents like Herceptin(R) (trastuzumab)."

Novel Human Tissue Transgenic Cancer Model May Offer Significant ...  -  Apr 18, 2007
Business Wire (press release),We have been very encouraged by the similarity to human patients in both histological appearance and response to agents like Herceptin ® (trastuzumab).�

Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference  -  Apr 16, 2007
PharmaLive.com (press release),...biomarker that guides the use of Herceptin(R) (Trastuzumab), another cancer biological therapy that applied a biomarker to obtain regulatory approval.

Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference  -  Apr 16, 2007
Business Wire (press release),...biomarker that guides the use of Herceptin® (Trastuzumab), another cancer biological therapy that applied a biomarker to obtain regulatory approval.

Taxane Use And Dose-Dense Scheduling May Benefit Patients With ...  -  Apr 14, 2007
Medical News Today (press release),This document attempts to provide some guidelines and a review of the recent data on adjuvant chemotherapy as it pertains to non-trastuzumab containing

Winners announced for prestigious biomedical award  -  Apr 13, 2007
CBC New Brunswick,Herceptin (trastuzumab) is an engineered protein that binds to a protein on human skin cells — the human epidermal growth factor receptor 2 (HER-2).

Genentech financially strong while Amgen struggles  -  Apr 13, 2007
BiopharmaReporter.com,Meanwhile, revenue for its highly-publicised breast cancer drug Herceptin (Trastuzumab) in the period was $311m, a 7 per cent increase compared to last year

Genentech Announces First Quarter 2007 Results  -  Apr 12, 2007
PharmaLive.com (press release),As previously announced, Genentech also made a "go" decision for a Phase III study of Omnitarg(TM) (pertuzumab), Herceptin(R) (Trastuzumab) and Taxotere

Genentech earnings soar but Lucentis sales slow down slightly  -  Apr 12, 2007
Pharma Times (subscription),As for Genentech's other key products, US sales of the breast cancer drug Herceptin (trastuzumab) climbed just 7% to $311 million, while Tarceva (erlotinib)

New Role For Sugars: Research Shows Connections Between Sugar ...  -  Apr 11, 2007
Medical News Today (press release),These are the same types of proteins that are targeted by a new generation of anti-cancer drugs such as Herceptin (trastuzumab).

Breast cancer death rate falling  -  Apr 11, 2007
Globe and Mail,And drugs including tamoxifen (trade named Nolvadex) and trastuzumab (Herceptin) are helping prevent recurrences. The new report, entitled Canadian Cancer

Genentech Announces First Quarter 2007 Results  -  Apr 11, 2007
Business Wire (press release),As previously announced, Genentech also made a “go� decision for a Phase III study of Omnitarg™ (pertuzumab), Herceptin® (Trastuzumab) and Taxotere versus

Recent Declines In Breast Cancer Mortality Greatest In Women Under 70  -  Apr 6, 2007
Medical News Today (press release),For example, adjuvant use of Herceptin (trastuzumab) was approved in November 2006 for HER-2+ breast cancer (many ER-negative breast cancers are HER2+).

Kosan Biosciences to Present at the CIBC World Markets Annual ...  -  Apr 5, 2007
PharmaLive.com (press release),Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc. CONTACT: Jane M. Green, VP, Corporate Communications of Kosan

Oncology Drug Development Update - EGFr-Targeted Drugs: Vectibix ...  -  Apr 5, 2007
Drug Newswire (press release),...is well established, required by FDA, and offers theragnostic value for treatment of women with breast cancer with Herceptin (trastuzumab; Genentech).

Biomarkers could drive future of Roche's Tarceva in lung cancer  -  Apr 5, 2007
Pharma Times (subscription),...breast cancer where detection of HER 2 positivity identifies patients who will respond to breast cancer treatment with Roche's Herceptin (trastuzumab).

Neoadjuvant Taxotere®, Navelbine® and Herceptin® Active for ...  -  Apr 4, 2007
Cancer Consultants (press release),Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvnt doxorubicin pluw cyclophosphamide in women with human

Roche expands antibody presence with THP purchase  -  Apr 2, 2007
DrugResearcher.com,This was mainly due to the success of their collaborative oncology drugs, Rituxan (rituximab) Herceptin (Trastuzumab) and Avastin (bevacizumab).

GSK files in Japan for Tykerb and in Europe for Globorix  -  Apr 2, 2007
Pharma Times (subscription),...with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received other therapies including Herceptin (trastuzumab).

GlaxoSmithKline to create 150 jobs in Cork over next five years  -  Mar 29, 2007
FinFacts Ireland,...or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab.

Avastin approved for metastatic breast cancer in EU  -  Mar 29, 2007
Pharma Times (subscription),...trial was initiated, called AVEREL, into HER2-positive breast cancer evaluating Avastin in combination with docetaxel plus Herceptin (trastuzumab).

Laws, Guidelines and professional choice  -  Mar 28, 2007
European Journal of Cardio-Thoracic Surgery (subscription)Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. National Institute for Health and Clinical Excellence, 71 High Holborn,

Genentech Q1 2007 Earnings Call Transcript  -  Apr 11, 2007
Seeking Alpha,...in combination with Rituxan as treatment for non-Hodgkin's lymphoma; and a Phase I Trastuzumab DM1 study for HER2-positive metastatic breast cancer.

Billion dollar babies—biotech drugs as blockbusters  -  Apr 3, 2007
Nature.com (subscription),Two targeted cancer therapies, Basel-based Novartis' Gleevec (imatinib mesylate), and Genentech's Herceptin (trastuzumab), are oft-cited examples of the

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional